CNN Quotes Dr. Michael Carome on FDA Approval of New Alzheimer’s Treatment
By By Jeffrey Toobin
“We believe that the FDA, starting back in 2019, worked in inappropriately close collaboration with Biogen,” said Carome, who testified at the advisory committee meeting against FDA approval of Aduhelm. “FDA became a partner with Biogen, and they made the decision about whether to approve the drug. They were not objective, unbiased regulators. It seems as if the decision was preordained.”
Read the full store here.